A commentary published in The Lancet in early 2026 argues that surgical approach represents a clinically consequential variable in long-term lung cancer outcomes, a position that synthesizes more than a decade of inconclusive perioperative research and points toward a more rigorous framework for future trial design.

The commentary arrives at a moment when thoracic surgery has undergone considerable technical evolution. Minimally invasive approaches, including video-assisted thoracoscopic surgery, robotic-assisted platforms, uniportal techniques, and monoportal procedures, have each gained adoption in major thoracic centers. Alongside these technical developments, enhanced post-surgical rehabilitation programs and multimodal treatment regimens incorporating neoadjuvant immunotherapy have reshaped the perioperative environment for patients with resectable lung malignancies. The cumulative effect of these changes has raised a persistent and unresolved question: whether the manner in which surgery is performed, and not merely whether it is performed, materially influences oncological outcomes over time.

The Translational Gap

For more than a decade, preclinical evidence has suggested that perioperative management decisions carry oncological weight. Laboratory and animal model data have indicated that the pharmacological agents selected during or after surgery, as well as the degree of surgical invasiveness, may modulate immune function and alter the tumor microenvironment in ways that affect the risk of residual disease proliferation and distant recurrence. These findings generated substantial interest and informed the design of multiple clinical investigations.

The translational record, however, has been discouraging. Clinical trials designed to test whether specific perioperative drug choices or reduced surgical invasiveness could lower recurrence rates have, to date, failed to produce results that confirm the preclinical signal. The commentary in The Lancet acknowledges this gap directly and characterizes it as a defining challenge for the field. Thoracic surgery is identified as a specialty where this failure has been particularly pronounced, given the volume of technical advancement occurring in parallel with the absence of confirmatory trial data.

The reasons for this translational difficulty are likely multifactorial. Heterogeneity in patient populations, variability in tumor biology, inconsistency in how surgical invasiveness is defined and measured across institutions, and the evolving standard of care during prolonged trial accrual periods all contribute to the interpretive complexity. Observational data, while hypothesis-generating, carry inherent confounding that randomized controlled trial (RCT) designs are meant to address. Yet the RCTs conducted thus far have not resolved the central question.

Why Surgical Approach May Matter

The biological rationale for an effect of surgical approach on oncological outcomes centers primarily on the perioperative immune response. Open thoracic surgery, relative to minimally invasive alternatives, involves greater tissue trauma, more pronounced systemic inflammatory responses, and more extensive disruption of the surgical field. These differences are not merely technical distinctions. They have measurable physiological correlates, including alterations in circulating cytokine profiles, natural killer cell activity, and markers of immune suppression in the immediate postoperative period.

Minimally invasive approaches reduce the magnitude of this surgical stress response. Whether that reduction is sufficient to alter the probability of micrometastatic disease establishing viable colonies during the perioperative window remains a question that has not been answered by prospective trial data. The preclinical literature suggests it should matter. The clinical literature, as the commentary notes, has not confirmed that it does, at least not through the evidence standard that would support practice-changing conclusions.

Anesthetic and analgesic choices represent a second channel through which perioperative management may influence tumor biology. Regional anesthetic techniques, opioid-sparing protocols, and the selection of specific volatile versus intravenous anesthetic agents have all been studied in relation to cancer recurrence. Some agents have demonstrated immunomodulatory properties in vitro. Again, however, translation to clinical outcomes data has been inconsistent, and no current guideline recommends a specific anesthetic protocol on the basis of oncological rather than hemodynamic or pulmonary considerations.

The Multimodal Treatment Context

The emergence of neoadjuvant immunotherapy as a component of treatment for resectable non-small cell lung cancer has added a further layer of complexity to interpreting surgical approach effects. When patients receive programmed death-ligand 1 (PD-L1) pathway inhibitors or combination immunotherapy regimens prior to surgical resection, the tumor microenvironment at the time of surgery differs substantially from what it would have been under a surgery-first approach. The immune contexture of the resected specimen, the degree of pathological response, and the residual burden of viable tumor cells are all altered.

Under these conditions, the question of whether surgical approach independently influences long-term outcomes becomes harder to isolate. Patients who achieve a major pathological response to neoadjuvant immunotherapy may enter the operating room with a substantially different oncological profile than those with limited response, and this difference may dwarf any effect attributable to the choice between a uniportal and a multiport thoracoscopic technique. Conversely, patients with incomplete pathological response may have residual disease that is more susceptible to the perioperative immune perturbations that minimally invasive surgery is hypothesized to attenuate.

Future trial designs will need to account for neoadjuvant treatment status explicitly, either through stratification at randomization or through subgroup analyses of sufficient statistical power to detect differential effects across treatment groups.

Implications for Trial Design

The commentary’s most substantive contribution may be its implicit challenge to the research community regarding how future trials should be structured. The pattern of well-designed preclinical work failing to produce concordant clinical results suggests that either the preclinical models do not adequately capture human tumor biology and immune dynamics, or that the clinical trials conducted to date have been insufficiently powered, inadequately designed, or poorly matched to the specific patient populations in whom the hypothesized effect would be most detectable.

Several design considerations merit attention. First, the definition of the surgical intervention itself requires standardization. Minimally invasive surgery encompasses a spectrum of techniques with varying degrees of port placement, camera systems, robotic assistance, and operative duration. Lumping these approaches into a single category for comparative purposes may obscure differential effects that exist within the minimally invasive category itself.

Second, the selection of endpoints requires careful consideration. Overall survival remains the gold standard in oncological trials, but the long follow-up periods required to detect survival differences introduce attrition, crossover, and the influence of subsequent therapies that dilute the signal attributable to the index surgical procedure. Disease-free survival and time to recurrence are more proximate endpoints, though their relationship to overall survival in the era of effective salvage therapies for lung cancer is not invariant.

Third, biomarker substudies embedded within surgical trials could help characterize the immune and inflammatory mediators that are hypothesized to link surgical approach to oncological outcomes. Circulating tumor DNA assessment at defined perioperative timepoints offers one mechanism for tracking residual disease burden in relation to surgical technique in a way that was not feasible in earlier trial generations.

The Hawaiian Patient Population

For clinicians practicing in Hawaii, the questions raised by the commentary carry additional dimensions. The state’s patient population reflects substantial ethnic heterogeneity, with notable representation of Native Hawaiian, Filipino, Japanese American, and other Pacific Islander communities. Lung cancer incidence and mortality patterns, as well as biological characteristics of lung tumors, vary across these populations. The immunological determinants of perioperative outcome may not be uniform across ancestral backgrounds, and any future trials that aim to be generalizable to the populations served by Hawaii’s thoracic surgery programs will need to engage with this heterogeneity rather than assume it away.

Access to specific surgical platforms also varies by institution and island. Robotic-assisted thoracoscopic surgery, for example, requires capital investment and credentialed surgical volume that not all facilities in the state currently maintain. The practical applicability of trial findings generated at high-volume mainland academic centers to community hospital settings in Hawaii merits consideration as evidence evolves.

What the Current Evidence Supports

The commentary does not advocate for a specific surgical technique on the basis of oncological superiority, and the available evidence base does not support such a recommendation. Minimally invasive approaches to lung resection carry established advantages in terms of perioperative morbidity, pulmonary function preservation, and length of hospital stay. These benefits are relevant and clinically meaningful on their own terms.

Whether those same approaches confer a reduction in long-term recurrence risk through immunological or other biological mechanisms remains a hypothesis rather than a demonstrated effect. The commentary argues that this question merits rigorous prospective investigation and that the field has not yet produced the trial that would settle it.

That assessment appears well-founded. The preclinical rationale is coherent, the biological plausibility is substantiated, and the clinical consequence of a genuine effect would be substantial given the volume of lung cancer resections performed annually. The absence of confirmatory evidence is not equivalent to evidence of absence, and the commentary appropriately frames the current situation as one calling for better-designed investigation rather than premature closure.

Thoracic surgery programs in Hawaii and elsewhere should follow the development of prospective comparative trials in this area with attention. If adequately powered randomized data emerge that link surgical approach to long-